Tau is the major neuronal protein involved in the stabilization of microtubule assembly. In Alzheimer`s disease, Tau self assembles to form intracellular protein aggregates, which are toxic to cells. Various methods have been tried and tested to restrain the aggregation of Tau. Most of the agents tested for this purpose have limitations in their effectiveness and availability to neuronal cells.
Introduction
Microtubule-associated protein Tau undergoes misfolding and forms intracellular aggregates in Alzheimer`s disease (AD) and related Tauopathies 1 . Deposition of extracellular fibrillar aggregates of amyloid-β also has deleterious effects on neuronal functions 2, 3 . Both the proteinaceous aggregates have been widely studied with respect to their pathological consequences in AD and form the basis of two hypotheses known as 'Tau' and 'amyloid-β' hypothesis. Tau hypothesis has attained more attention in last decade since only amyloid-β deposition are found in brain without any pathological effect 4 . The main physiological functions of Tau include the stabilization of microtubule, axonal growth and cargo trafficking etc. Under pathological condition, a series of signalling cascade leads to phosphorylation of Tau by various kinases. Tau is hyperphosphorylated upon upregulation of several kinases like CDK5 and GSK-3β. Therapeutic strategies have been employed involving the use of specific kinase inhibitors [5] [6] [7] . CDK5 complexed with p25 increases its activation state and induces the phosphorylation of Tau at the following amino acids Ser202, Thr205, Ser235 and Ser404.
Additionally, the amyloidogenic protein aggregates accumulate around the phospho-lipid bilayer which leads to the formation of membrane pore in cholesterol-rich domain 8, 9 . AD is associated with a multiple factors, which ultimately lead to neurodegeneration. Thus, multi-targeted approach is required for the effective amelioration of Tau-mediated neuropathology 10 . Therapeutic strategies have been studied involving different aspects of neurodegeneration. A wide range of small molecules with multiple targets like aggregation inhibition, kinase inhibition or phosphatase activation are under study 7 . Melatonin is a neurohormone-derived from pineal gland and involved in the maintenance of circadian rhythm 11, 12 . Melatonin is also produced in non-pineal sites and its receptors are present in most cell types 13, 14 . It is rapidly metabolized in liver and converted to secondary metabolites called kynuramines [15] [16] [17] . It is well known that melatonin is an anti-oxidant molecule, which can cross all biological membranes and also functions in the upregulation of other enzymes involved in protection against oxidative damage [18] [19] [20] [21] [22] [23] . Melatonin is a pleotropic molecule with a high bioavailability and low toxicity. It is considered as a potent candidate against neurodegenerative diseases due to its wide range of functions. The role of melatonin in kinase function has been studied where it was found to downregulate kinases like GSK-3β and PKA, which in turn affects the phosphorylation status of Tau [24] [25] [26] [27] . Melatonin is found to be effective in amelioration of neurological defects and restoration of cognitive functions 28, 29 . Melatonin has also been studied with respect to inhibition of amyloid-β and α-synuclein aggregation 30, 31 . The multi-faceted role of melatonin makes it a potent lead for therapeutic approach 32 .
Here, we have studied the potential role of melatonin in inhibition of full-length Tau (4R2N) aggregates and its effect on cell viability. We have also performed the function of melatonin in CDK5-mediated phosphorylation of Tau (Ser202/Thr205: AT8) sites. Melatonin reduces the membrane roughness induced by Tau aggregates in neuro2A and N9 microglial cells while the tubulin network remain unaltered by melatonin and Tau aggregates.
Materials and methods

Materials
Melatonin, BES, MES, Glycine, SDS, ThT, Protease inhibitor cocktail and ANS were purchased from Sigma-Aldrich. Other biochemical or molecular biology grade chemicals used were -DTT and IPTG (Calbiochem), APS, NaCl, PMSF, Sodium Azide, Ampicillin (MP Biomedicals), Luria-Bertani broth (Himedia), Acrylamide, EGTA, TEMED, DMSO (Invitrogen). BCA assay reagents used for protein estimation were purchased from Sigma-Aldrich,. Filtration devices were used from Merck and Pall 
Protein expression and Purification
pT7C full-length Tau (hTau40wt) were expressed in E.coli BL21* upon induction by 0.5 mM IPTG and purified as previously described [33] [34] [35] . Cell homogenization was carried out at 15 KPSI using 
Aggregation inhibition assay
Full-length Tau aggregates were prepared in 20 mM BES pH 7.4 as assembly buffer, in the presence of heparin as an inducer (Tau: heparin= 4:1) 36 . The reaction was set-up in microcentrifuge amber tubes and incubated at 37˚C for 96 hours. Aggregation reaction tubes with 200-5000 µM of melatonin in 10% DMSO were also prepared. ThT fluorescence for all reactions at various time-points (0-96 hours) was measured at 450 nm excitation and 475 nm emission wavelengths. The measurements for all time-points were taken in triplicates with Tau and ThT ratio of 1:2. Fluorescence of assembly buffer was measured for blank subtraction.
CD spectroscopy
CD spectra for 3 µM soluble Tau and Tau aggregates with or without melatonin were recorded in Jasco J-815 CD spectrometer in 1 mm cuvette under nitrogen atmosphere. The spectra were recorded at 100 nm/min scan speed at 1 nm bandwidth in 190-250 nm scan range. The baseline was recorded for 50 mM sodium phosphate buffer pH-6.8 and subtracted for each spectrum. The final spectra were obtained as an average of five CD acquisitions.
Transmission Electron Microscopy
Morphology of Tau aggregates with or without melatonin were visualized by transmission electron microscopy. 2 µM of Tau aggregates were placed on 400 mesh carbon coated copper grids, washed twice with filtered miliQ water for 30 seconds and stained with 2% uranyl acetate for 2 minutes. The samples were scanned using TECNAI T20 Transmission Electron Microscope at 120 KV. 
Size-exclusion chromatography
Cytotoxicity assay for SEC fractions
The fractions obtained from size-exclusion chromatography of full-length Tau aggregates in presence or absence of 1000 µM melatonin were tested for their effect on viability of neuro2A cells (Fractions F7-F10 corresponds to Tau with melatonin, Fractions F11-F14 corresponds to Tau only from SEC).
Neuro2A cells were cultured in DMEM with 10% FBS and 100µg/mL of penicillin and streptomycin.
Neuro2A cells were seeded in 96 well plates (10000 cells/well) and incubated at 37°C for 12 hours at 5% CO2. Peak fractions (F7-F10) were obtained from SEC of full length Tau with melatonin and fractions (F11-F14) were obtained from SEC of Tau aggregates. Cells were treated with 30 µl of fractions and 70 µl of reduced serum media (DMEM with 0.5% FBS) in each well and incubated for 24 hours. MTT assay was performed to check the cell viability. MTT was added at 0.5 mg/ml concentration in each well and incubated for 3 hours. The formazan end product solubilized by adding absolute DMSO. The spectrophotometric absorbance was measured at 570 nm in triplicate (Tecan Infinite 200 Pro).
Real-time PCR
Neuro2A cells were treated with melatonin (50 µM) and okadaic acid (25 nM) for 6 hours. Then the cells were washed in PBS and total RNA were isolated by the conventional TRIZOL, chloroform and isopropanol procedure. The RNA pellets were proceeded for cDNA synthesis (First-strand cDNA synthesis kit) with oligo-dT primer. The expression level of CDK5 was checked by quantitative PCR.
The fold change was calculated by ΔΔCT method with respect to house-keeping GAPDH control (Table 1) .
Western Blot
Neuro2A cells with okadaic acid (25 nM) and melatonin (50 µM) separately and together for 24 hours. The cells were washed with PBS, lysed with RIPA buffer and cell lysate were subjected to western blot with anti-CDK5 monoclonal antibody (1:1500) with β-tubulin (1:5000). Then, the bands intensity was quantified by using BIORAD Quality one 4.6.6 software. The band-density of the treated groups were compared with its corresponding untreated control group and the relative fold changes were plotted with respective proteins and treated group. The images and 3D localization (orthogonal view) were observed in Zeiss Axio observer with Apotome2 fluorescence microscope at 63X oil immersion and analyzed by ZEN2 software.
Immunofluorescence microscopy
Surface morphology by Field-Emission Scanning electron microscopy (FE-SEM)
To study the surface morphology of neuro2A and microglia (N9) cells by melatonin and Tau aggregates treatment, the cells were grown onto coverslip for 16 hours at 37°C, 5% CO 2 . Then the cells were washed with PBS twice and treated individually and in combination with 10 µM of Tau aggregates and 50 µM of melatonin for 6 hours. After the treatment, cells were fixed with 2.5% 
Results and discussion
Melatonin shows no effect on aggregation of full-length Tau
The effect of melatonin in the inhibition of full-length Tau protein ( Fig. 1A) aggregation was studied using ThT fluorescence assay. Melatonin was used against Tau aggregation at a concentration range of 200-5000 µM. Surprisingly, it did not show any significant effect on the aggregation of full-length Tau protein in ThT fluorescence, even with higher concentration (5000 µM) of melatonin ( Fig. 2A) .
Also, CD spectroscopy revealed that melatonin treatment does not bring about significant structural change. Tau aggregates shows the signature for β-sheet structure, which remained unchanged with melatonin treatment (Fig. 1C) . However, the electron microscopy images for full-length Tau aggregation samples in presence of melatonin at 1000 and 5000 µM showed distinct morphology of Tau fibrils where mostly broken filaments were observed (Fig. 1D ). Melatonin has been studied earlier in the inhibition of amyloid-β and α-synuclein aggregates 30 . The mode of action of melatonin involves the disruption of salt-bridge formation or reducing the hydrophobic interaction between proteins 31, 37 . For Tau aggregation inhibition, melatonin may employs the same mechanism but it is required in higher concentration to disrupt the fibril formation.
Melatonin reduces the formation of higher order oligomeric species of Tau
The aggregation of Tau protein forms intermediate toxic oligomers, which also act like seeding species for further aggregation 38 . We prepared Tau aggregates in the presence or absence of melatonin and carried out SEC for the separation of oligomeric species 39 . For the preparation of oligomers, full-length Tau was incubated at 37 ˚C in the presence of heparin with or without melatonin. Size-exclusion chromatography (SEC) was performed after 24 hours to separate these oligomers and to see its effect on viability of neuro2a cells upon exposure. When the aggregates were prepared in presence of melatonin, the higher order oligomer were not observed in SEC. In SEC experiment, the peak for full length Tau oligomeric species of lower order was obtained as suggested by the retention volume. These oligomeric species were absent in SEC of full-length Tau aggregates in the presence of melatonin (indicated by downward red arrow) ( Fig. 2A) . The fractions collected from SEC for full-length Tau aggregates and corresponding fractions from SEC for Tau aggregates with melatonin showed no cytotoxicity when treated to neuro2A cells. It also had no effect on morphology of cells after treatment for 24 hours ( Fig 2C) probably due to the lower oligomer concentration or non-toxic forms of oligomer species. The results showed that melatonin can effectively inhibit the formation of these oligomeric species. (Fig. 3A, B , C) while OA-induced the CDK5 level in melatonin-treated neuro2A cells as seen by immunostaining ( Fig. 3D ). CDK5 level remains unaltered at different treatment group as observed by fluorescence microscopy (Fig. 3E) .
Phospho Tau (AT8) and CDK5 levels remained unaltered by melatonin
To confirm the localization of p-Tau into the neuro2A cells upon same treatment, cells were immunostained with AT8 antibody along with total-Tau K9JA antibody as a control. Neuroblastoma cells have expressed a constant level of intracellular AT8 epitope of Tau (Fig. 4A) whereas; OA and melatonin treatment did not alter basal level phospho-Tau expression inside the nucleus (Fig. 4B) . In our study, we have showed the constant level of CDK5 and AT8-Tau throughout the groups. This signifies that okadaic acid as well as melatonin did not involve in CDK5-mediated Tau phosphorylation.
Alteration of membrane morphology and Tubulin network by Tau aggregates and melatonin
The plasma membrane topography is a determinant of normal physiological or pathological state of neuro-glial cells. The alteration of membrane structure occurs either due to changes in raft region or the variation of cytoskeleton configuration. The membrane topography can be broadly two types: roughness and stiffness. Aβ which is one of the key protein responsible for AD, increases membrane stiffness 42 whereas; Taxol reduces membrane roughness by stabilizing microtubules 43 . Neuro-glial cells when treated with Tau aggregates, it induced membrane roughness as compared to without treatment control cells (Fig. 5A ). The membrane roughness was more in case of neuro2A cells (Fig.   5A ) whereas; bulging type structures were more prominent in N9 cells (Fig. 6A) . As it is well proved that Tau is a microtubule stabilizing protein and Tau aggregation leads to microtubule disorganization during AD, extracellular Tau aggregates may influence the cytoskeleton mis-orientation as found by (Fig. 5, 6A) .
Microtubules stabilize the cell shape, structure and facilitate several plasmalemma events-like migration, exosomal release, endocytosis, induction of signalling cascade etc. To study the effect of Tau aggregates and melatonin on cytoskeletal network, cellular tubulin was immune-stained after the same treatments as mentioned above. Extracellular Tau aggregates-induced unaltered tubulin patches in the cytoplasm whereas; melatonin treatment showed intense tubulin network in neuro2A cells (Fig.   5B ). Tau aggregates treatment might activate the microglia with more extended cell bodies compared to untreated control. Melatonin treatment did not alter the microtubule network in microglia (Fig. 6B) .
In our study, we evidenced the initiation of membrane roughness on neurons and microglial cells upon Tau fibrils exposure. But the event was reinstated by melatonin which signifies its role in remodelling of membrane dynamics and cell-to-cell communication in neurodegenerative diseases.
Conclusion
Melatonin is a neurohormone, which serves a wide variety of function apart from maintenance of circadian rhythm. It mediates its cytoprotective action as an anti-oxidant itself as well as regulator of other proteins involved in anti-oxidant and anti-inflammatory function. Our studies shows in vitro administration of melatonin does not affect the aggregation of full-length Tau but it does reduce higher order oligomers. Melatonin also affected Tau phosphorylation and helps to maintain tubulin network and membrane topology in neuro2a and N9 cells.
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